Intellectual property from fibrolamellar discovery dedicated to the public
Intellectual property resulting from the discovery of specific DNA mutations linked to fibrolamellar hepatocellular carcinoma, has been dedicated to the public by the institutions that made the discovery, The Rockefeller University (“Rockefeller”) and the New York Genome Center (“NYGC”). The institutions made this unusual move in the hope of accelerating progress toward the delivery of diagnostics and therapies for this devastating disease. For additional information click the link above.
Major fibrolmellar research published in Science Magazine
A research paper on genetic mutation in fibrolamellar tissue was published February 28, 2014. This research was conducted at the Tucker Davis Research Facility at Rockefeller University. Dr. Sandy Simon is head of the laboratory and his daughter Elana, who is a fibrolamellar patient, was a lead researcher.
Fibrolamellar Tissue Repository opens at the Tucker Davis Research Facility at Rockefeller University.Research on fibrolamellar hepatocellular carcinoma depends on the continued involvement of patients, families and researchers alike. Donations of fibrolamellar tissue are central to the scientific research that will improve the diagnosis, treatment and understanding of this rare disease. The Fibrolamellar Tissue Repository is a tissue bank for fibrolamellar samples obtained during surgery. All patients and families should read this link for details about donating tissue samples.
Memorial Sloan-Kettering has added specific reference to fibrolamellar liver cancer on their website.This information is very comprehensive and includes sections on symptoms, diagnosis, risk factors, and treatment options
The above website reference also includes the following research news information. FCF has helped to fund the clinical trial referenced below. More information about the trial, eligibility and the specific link to this trial at clinicaltrials.gov can be found here.
ARTICLES ON FIBROLAMELLAR
"Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis", http://www.nature.com/modpathol/journal/v18/n11/full/3800449a.html
"Fibrolamellar carcinoma of the liver: An immunohistochemical study of nineteen cases and a review of literature", (only a preview…have to purchase to read the entire thing) http://www.sciencedirect.com/science/article/pii/S0046817788802612
"Guidelines for the Diagnosis of Hepatocellar Carcinoma (HCC) in Adults", http://gut.bmj.com/content/52/suppl_3/iii1.long
"Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma", http://jco.ascopubs.org/content/21/3/421.full
"A Translational Study Case Report on the Samll Molecule Emergy Blocer 3-Bromopyruvate (3BP) as a Potent Anticancer Agent: From Bench Side to Bedside - Report on the novel anti-cancer agent 3BP -
"Fibrolamellar Carcinoma: 2012 Update" by Dr. Michael Torbenson, http://www.scientifica.com/2012/743790/
"Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma" - this is a singular case study.
"Fibrolamellar Carcinomas are Positive for CD68" - Modern Pathology (2010)
Fibrolamellar carcinomas are a unique type of liver carcinoma that arise in non-cirrhotic livers of young individuals. Despite their distinctive appearance, recent studies have demonstrated a lack of consistency in how fibrolamellar carcinomas are diagnosed by pathologists. Read more
"Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma"
DNAJB1-PRKACA is specific for fibrolamellar carcinoma - co-authored by FCF Scientific Advisory Board member Michael Torbenson from Mayo Clinic.
Article abstract discussing arginine therapy for high ammonia levels in the meeting abstracts of the Society of Hospital Medicine.